Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation and miRNA-M371 Biomarker Study for Stage IIa/IIb Seminomas
NCT05529251Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2022
- Primary completion
- May 2032
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, etoposide and Cisplatin micelle injection (HA132) in seminoma (4 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-Free Rate at 36 months. Started Sep 2022; status: recruiting.
02
Drugs
carboplatinetoposideCisplatin micelle injection (HA132)
03
Conditions
seminoma
Beyond the preview
Go deeper on NCT05529251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529251.